Commentary
Video
Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS
In Partnership With:
Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.
In this recap of an OncLive® State of the Science Summit™ on Lung Cancer chaired by Isabel Preeshagul, DO, MBS, she and colleagues highlight key takeaways from their presentations, which covered updates from across the lung cancer treatment paradigm. Preeshagul is a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center.
Preeshagul discusses the clinical implications of data from the phase 3 ADRIATIC trial (NCT03703297), which showed that patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy experienced a median overall survival of 55.9 months (95% CI, 37.3-not evaluable) when treated with durvalumab (Imfinzi; n = 264) compared with 33.4 months (95% CI, 25.5-39.9) when given placebo (n = 266; HR, 0.73; 95% CI, 0.57-0.93; P = .0104). Based on these data, In August 2024, the FDA granted priority review to the supplemental biologics license application seeking the approval of durvalumab for the treatment of patients with LS-SCLC whose disease has not progressed following platinum-based concurrent chemoradiotherapy.
Next, Alissa J. Cooper, MD, a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center, highlights the evolving understanding of the role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer (NSCLC). Cooper expands on the challenges posed in the clinical study of these agents and how biomarkers could help refine the understanding of which patients may benefit most from these agents.
Kathryn C. Arbour, MD, a thoracic medical oncologist and assistant attending physician at Memorial Sloan Kettering Cancer Center, then delves into the current treatment paradigm for patients with NSCLC harboring KRAS G12C mutations. She details the prevalence of KRAS mutations in this patient population and how ongoing research could build upon the targeted therapies available for those with KRAS G12C mutations and other KRAS alterations.
Interested in attending a future State of the Science Summit or Institutional Perspectives in Cancer meeting? Check out the list of upcoming events!
